4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
April 2025 in “BMC Immunology” Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
36 citations
,
January 2003 in “Molecular and Cellular Biochemistry” March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
10 citations
,
January 1994 in “Advances in pharmacology” New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
July 1993 in “Inpharma Weekly” Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.
February 2010 in “Journal of The American Academy of Dermatology” Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.
17 citations
,
April 2016 in “Journal of Investigative Dermatology” KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.
1 citations
,
April 2008 in “Progrès en Urologie” Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
215 citations
,
March 2011 in “Clinical Cancer Research” Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.
June 2013 in “Annals of the rheumatic diseases” Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
August 2022 in “Dermatology Online Journal” Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
37 citations
,
September 2003 in “Journal of Medicinal Chemistry” A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.
January 2021 in “Research Portal Denmark” Tofacitinib helped a man with alopecia totalis regrow all his hair.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
17 citations
,
June 2020 in “British Journal of Dermatology” Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.